CAR T-cell update: therapy improves outcomes for patients with B-cell lymphoma

An international phase-2 trial of a CAR T-cell therapy found that 52 percent of patients responded favorably.

Can you inherit gastrointestinal cancer?
New checkpoint inhibitor shows promise in clinical trial for non-Hodgkin’s lymphoma